Mirvetuximab soravtansine在FRα阳性、三线及以上复发性铂敏感卵巢癌中的疗效与安全性:单臂II期PICCOLO试验
PICCOLO是一项全球、开放标签、单臂II期试验,评估MIRV(6 mg/kg调整理想体重,每3周一次)用于FRα阳性(≥75%细胞≥2+染色强度)复发性铂敏感卵巢癌的三线及以上治疗。79例可评估疗效者客观缓解率为51.9%(95%CI 40.4%~63.3%),中位缓解持续时间8.25个月,中位无进展生存期6.93个月。未出现新的安全性信号,常见治疗中出现的不良事件为胃肠道、神经感觉和可消退的眼部事件。
要点
- MIRV用于FRα阳性复发性铂敏感卵巢癌≥3线治疗,客观缓解率51.9%(95%CI 40.4%~63.3%)。
- 中位缓解持续时间8.25个月(95%CI 5.55~10.78个月),中位无进展生存期6.93个月(95%CI 5.85~9.59个月)。
- 16%的参与者因治疗中出现的不良事件停药,3%的参与者因治疗中出现的不良事件死亡。
核心结论
- MIRV作为≥3线治疗在经重度治疗的复发性FRα阳性铂敏感卵巢癌中显示出显著疗效和可耐受的安全性,包括在既往PARPi治疗期间或30天内出现疾病进展的患者中。
研究设计与样本
- PICCOLO是一项全球、开放标签、单臂II期试验,纳入FRα阳性(≥75%细胞≥2+染色强度)复发性铂敏感卵巢癌患者,接受MIRV 6 mg/kg调整理想体重每3周一次治疗直至疾病进展、不可接受毒性、撤回知情同意或死亡。
- 共79例参与者入组并可评估疗效,主要终点为研究者评估的客观缓解率,关键次要终点为研究者评估的缓解持续时间。
主要发现
- 主要终点达到,客观缓解率为51.9%(95%CI 40.4%~63.3%)。
- 中位缓解持续时间为8.25个月(95%CI 5.55~10.78个月),中位无进展生存期为6.93个月(95%CI 5.85~9.59个月)。
- 数据截止时总生存期未成熟。
- 在既往PARPi治疗期间或30天内出现疾病进展的参与者(n=59)中客观缓解率为45.8%(95%CI 32.7%~59.2%),在既往PARPi治疗无疾病进展的参与者(n=5)中客观缓解率为60.0%(95%CI 14.7%~94.7%)。
- 未出现新的安全性信号;最常见的治疗中出现的不良事件为胃肠道、神经感觉和可消退的眼部事件;13例参与者(16%)因治疗中出现的不良事件停药,2例参与者(3%)因治疗中出现的不良事件死亡。
关键数值与推荐
- FRα阳性定义为≥75%的细胞具有≥2+染色强度。
- MIRV给药方案为6 mg/kg调整理想体重每3周一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a phase II, global, open-label, single-arm trial of MIRV as third-line or greater (≥3L) treatment in patients with FRα-positive (≥75% of cells with ≥2+ staining intensity) recurrent platinum-sensitive ovarian cancer (PSOC). PATIENTS AND METHODS: Participants received MIRV (6 mg/kg adjusted ideal body weight every 3 weeks) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death. Primary endpoint was investigator-assessed objective response rate (ORR). Key secondary endpoint was investigator-assessed duration of response (DOR). Additional endpoints included investigator-assessed progression-free survival (PFS), overall survival (OS), and safety. Analyses of subgroups by disease characteristics (e.g. platinum-free interval) and treatment history [e.g. prior bevacizumab and poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor (PARPi) treatment] were exploratory. RESULTS: Seventy-nine participants were enrolled and efficacy assessable. The primary endpoint was met; ORR was 51.9% [95% confidence interval (CI) 40.4% to 63.3%]. Median DOR was 8.25 months (95% CI 5.55-10.78 months) and median PFS was 6.93 months (95% CI 5.85-9.59 months). OS was not mature at data cut-off. ORR was 45.8% (95% CI 32.7% to 59.2%) in participants with PD while on/within 30 days of prior PARPi (n = 59) and 60.0% (95% CI 14.7% to 94.7%) in those without PD with prior PARPi (n = 5). No new safety signals occurred; most common treatment-emergent adverse events (TEAEs) were gastrointestinal, neurosensory, and resolvable ocular events. TEAEs led to discontinuation in 13 participants (16%) and death in 2 participants (3%). CONCLUSIONS: MIRV as ≥3L treatment in heavily pretreated recurrent FRα-positive PSOC demonstrated notable efficacy and tolerable safety, including among those with prior PD on or within 30 days of PARPi (NCT05041257).
引用
- Alvarez Secord A, Lewin SN, Murphy CG, et al. The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2024. PMID: 39617145. doi:10.1016/j.annonc.2024.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。